ライフサイエンスコーパス: 5-HT(1A) receptor

1 elective, with subnanomolar affinity for the 5-HT1A receptor.

2 ike effect of D1 and possible involvement of 5-HT1A receptor.

3 intrinsic activity (E max = 26 +/- 2.0%) on 5-HT1A receptor.

4 ceptor in recombinant cells expressing human 5-HT1A receptor.

5 at serotonin is primarily acting through the 5-HT1A receptor.

6 hypothalamus and hippocampus is mediated by 5-HT1A receptors.

7 ed with the known postmortem distribution of 5-HT1A receptors.

8 ylpiperazine ([(18)F]MPPF), an antagonist of 5-HT1A receptors.

9 A, gamma-aminobutyric acid (GABA)B , BZ, and 5-HT1A receptors.

10 HT to a concentration sufficient to activate 5-HT1A receptors.

11 rotonin transporter (SERT) and serotonin 1A (5-HT1A) receptor.

12 h potency and efficacy were increased at the 5-HT(1A) receptor.

13 ilar to the agonist-induced responses of the 5-HT(1A) receptor.

14 hether protection required activation of the 5-HT(1A) receptor.

15 use and human MC respond to 5-HT through the 5-HT(1A) receptor.

16 e on the expression of the gene encoding the 5-HT(1A) receptor.

17 a high affinity (0.1 nM) and selectivity for 5-HT(1A) receptors.

18 at its main pharmacology is mediated via the 5-HT(1A) receptors.

19 sitization rather than downregulation of DRN 5-HT(1A) receptors.

20 ow produce functional desensitization of DRN 5-HT(1A) receptors.

21 eptor domains and substitutes for endogenous 5-HT(1A) receptors.

22 10 specific binding in brain regions rich in 5-HT(1A) receptors.

23 selectivity for 5-HT(2A) versus 5-HT(2C) and 5-HT(1A) receptors.

24 e first promising agonist PET tracer for the 5-HT(1A) receptors.

25 ining NMDA receptor is the primary target of 5-HT(1A) receptors.

26 t inhibited by activation of the 5-HT(5A) or 5-HT(1A) receptors.

27 hereby could provide a measure of functional 5-HT(1A) receptors.

28 ng in CHO cells expressing the serotonin-1A (5-HT(1A)) receptor.

29 , pretreatment with a specific antagonist of 5-HT1A receptors, 4-iodo-N-[2-[4-(methoxyphenyl)-1-piper

30 Because 5-HT(1A) receptor (5-HT(1A)R) internalization has been p

31 diating the intracellular traffic of the rat 5-HT(1A) receptor (5-HT(1A)R) toward dendrites.

32 ne ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand 3.

33 paring Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessential G(i)-coupled recept

34 the lipid dependence of the human serotonin 5-HT1A receptor, a GPCR that is central to neuronal func

35 Taken together, these results suggest that 5-HT(1A) receptor activation is a critical step in the a

36 to reveal the motivational mechanism whereby 5-HT(1A) receptor activation modulates drinking behavior

37 of drug alone via a mechanism dependent upon 5-HT(1A) receptor activation.

38 suppress the antidepressant-like effects of 5-HT1A receptor activation.

39 f so, whether the increase is dependent upon 5-HT1A receptor activation.

40 5-HT(1D) receptors, it exhibited appreciable 5-HT(1A) receptor affinity.

41 his study, we radiolabeled the high-affinity 5-HT(1A) receptor agonist (18)F-F13714 and investigated

42 n of caudal MR serotonergic neurons with the 5-HT(1A) receptor agonist (R)-(+)-8-hydroxy-2(di-n-propy

43 xetine attenuated hypothermia induced by the 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)

44 thesis using bilateral microperfusion of the 5-HT(1A) receptor agonist 8-hydroxy-2-(di-n-propylamino)

45 The selective 5-HT(1A) receptor agonist 8-hydroxy-2-dipropylaminotetra

46 Microinjections of the 5-HT(1A) receptor agonist 8-OHDPAT (0.1, 1.0 and 3.0 nmo

47 (S)-2 proved to be a potent 5-HT(1A) receptor agonist highly selective over alpha(1)

48 he effect of citalopram, whereas exposure to 5-HT(1A) receptor agonist only moderately influenced mal

49 rone treatment attenuated the effects of the 5-HT(1A) receptor agonist, (+/-)-8-hydroxy-2-(di-n-propy

50 s were used to test the possibility that the 5-HT(1A) receptor agonist, 8-hydroxy-2-(di-N-propylamino

51 The 5-HT(1A) receptor agonist, 8-OH-DPAT, reduced cAMP accum

52 receptor agonist, apomorphine (APO) and the 5-HT(1A) receptor agonist, 8-OHDPAT (8OH) in a low dose

53 Moreover, 5-HT(1A) receptor agonist-induced hypothermia is blunted

54 Treatment with the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylmino)tet

55 tested for behavior under effective doses of 5-HT1A receptor agonist 8-hydroxy-N, N-dipropyl-2-aminot

56 ted following systemic administration of the 5-HT1A receptor agonist, 8-OH-DPAT, the D2 receptor anta

57 Treatment with another 5-HT1A receptor agonist, buspirone (1.5 mg/kg, i.p.), re

58 Identical results were obtained with another 5-HT1A receptor agonist, buspirone (1.5 mg/kg, i.p.; n =

59 te brain, in contrast to 8-OH-DPAT, a potent 5-HT1A receptor agonist.

60 Three 5-HT1A receptor agonists (8-OH-DPAT, F13714 and F15599)

61 We conclude that 5-HT1a receptor agonists have two competing effects: rap

62 t years, new chemical entities targeting the 5-HT(1A) receptor (alone or in combination with other mo

63 affinities and functional activities for the 5-HT(1A) receptor and 5-HT transporter.

64 5-HT(1A) receptor and alpha(1)-adrenoreceptor (alpha(1)-

65 h K(i) values of approximately 30 nM for the 5-HT(1A) receptor and K(i) values of 5 and 0.5 nM for th

66 series possessed high affinity for the human 5-HT(1A) receptor and many displayed potent antagonist a

67 mal binding) of ((3)H)-WAY 100635 binding to 5-HT(1A) receptors and ((3)H)-ketanserin binding to 5-HT

68 eir in vitro pharmacological profile at both 5-HT(1A) receptors and alpha(1)-adrenoceptor subtypes wa

69 er, curcumin treatment, via up-regulation of 5-HT(1A) receptors and BDNF, may reverse or protect hipp

70 The effects of 5-HT were mediated via 5-HT(1A) receptors and required the function of Galpha(i

71 f dihydrofuroaporphine bind to the serotonin 5-HT1A receptor and exert opposite effects.

72 Further investigation into the role of the 5-HT1A receptor and the potential of [11C]-WAY100635 PET

73 bited these cells directly via activation of 5-HT1A receptors and indirectly via enhanced GABA releas

74 measured in brain is dominated by binding to 5-HT1A receptors and to reveal the extent of defluorinat

75 receptors, direct or indirect stimulation of 5-HT(1A) receptors, and to a lesser extent, reduction in

76 onto Receptor (Type II) cells by activating 5-HT1A receptors, and reducing ATP secretion.

77 -HT release throughout the DR, activation of 5-HT1A receptors, and subsequent inhibition.

78 profile of 5-HT(1A-1D) and 5-HT2 receptors, 5-HT1A receptors, and the serotonin (5-HT) transporter (

79 ing of pallidal neurons through postsynaptic 5-HT1A receptors; and (3) 5-HT postsynaptically excites

80 a and 4ccis emerged as novel and interesting 5-HT(1A) receptor antagonist (pK(i) = 8.70) and a 5-HT(1

81 n of fluoxetine (Prozac), others receiving a 5-HT(1A) receptor antagonist (WAY 100,635; Sigma, St. Lo

82 , its prevention by chronic treatment with a 5-HT(1A) receptor antagonist (WAY-100,635) did not preve

83 at the dosages used in this experiment, the 5-HT(1A) receptor antagonist WAY 100,635 may have positi

84 The selective 5-HT(1A) receptor antagonist WAY100135 (10 microM) block

85 onin (5-hydroxytryptamine, 5-HT), as did the 5-HT(1A) receptor antagonist WAY100635.

86 by pretreatment with WAY-100635, a serotonin 5-HT(1A) receptor antagonist, in DAT-KO mice, but the dr

87 avoidance learning may be stimulated by the 5-HT(1A) receptor antagonist.

88 nists (8-OH-DPAT, F13714 and F15599) and one 5-HT1A receptor antagonist (MPPF) were compared in terms

89 Instead, CUMI-101 behaved as a potent 5-HT1A receptor antagonist by dose-dependently inhibitin

90 nduced increase in social behaviors, while a 5-HT1A receptor antagonist did not alter affiliative voc

91 infused with WAY100635 (400 to 2000 ng), the 5-HT1A receptor antagonist did not facilitate lordosis r

92 CUMI-101 behaves as a 5-HT1A receptor antagonist in primate brain, with signif

93 udy showed that CUMI-101 behaved as a potent 5-HT1A receptor antagonist in rat brain.

94 ntagonist SB 216641 (10 microM), but not the 5-HT1A receptor antagonist WAY 100635 (10 microM) or the

95 y 8-OH-DPAT persisted in the presence of the 5-HT1A receptor antagonist WAY-100635, was abolished by

96 antagonist), WAY-100635 (selective serotonin 5-HT1A receptor antagonist) as well as monoamine oxidase

97 1D/1A) receptor antagonist) or WAY 100635 (a 5-HT1A receptor antagonist).

98 contribute to propranolol's action since the 5-HT1A receptor antagonist, (S)-WAY 100135 (P = 0.2), an

99 n emission tomography imaging and a specific 5-HT1A receptor antagonist, [carbonyl-11C]WAY-100635.

100 rying concentrations (200 to 2000 ng) of the 5-HT1A receptor antagonist, N-[2[4-(2-methoxyphenyl)-1-p

101 5-HT2C receptor antagonist, SB242084, or the 5-HT1A receptor antagonist, WAY-100635, and were tested

102 ing serotonin (5-HT) reuptake inhibitors and 5-HT1A receptor antagonists.

103 tative differences in the mechanisms whereby 5-HT(1A) receptors are able to inhibit stimulation of ad

104 studies suggest that spinal and supraspinal 5-HT(1A) receptors are involved in multiple inhibitory m

105 Inhibitory 5-HT(1a) receptors are located on serotonin (5-HT) neuro

106 ypercapnia, but not to hypoxia, and that MRR 5-HT1A receptors are also involved in thermoregulation a

107 Presynaptic dorsal raphe neuron (DRN) 5-HT1A receptors are known to have a critical role in af

108 The 5-HT1A receptors are located both presynaptically and po

109 Serotonin 1A (5-HT1A) receptors are involved in several physiological

110 ally interesting to consider and justify the 5-HT(1A) receptor as a new attractive target for drug di

111 formance and 3H-8-OH-DPAT-labeled binding of 5-HT(1a) receptors as well as 125I-LSD-labeled binding o

112 g and is a partial agonist for the serotonin 5-HT(1A) receptors as well as possessing low affinity an

113 hippocampus while increasing the efficacy of 5-HT1A receptors as measured by agonist-stimulated [35S]

114 pharmacology showed that focal activation of 5-HT1A receptors at the axon initial segment (AIS), but

115 ANOVA of 5-HT(1A) receptor availability demonstrated a significan

116 is was not associated with MAO-A genotype or 5-HT(1A) receptor availability in these regions.

117 MAO-A activity were associated with greater 5-HT(1A) receptor availability in women, but not in men.

118 we investigated the relationship between DRN 5-HT1A receptor availability and amygdala reactivity to

119 processing and the relationship between DRN 5-HT1A receptor availability and amygdala reactivity.

120 Alterations in DRN 5-HT1A receptor availability cause phenotypes characteri

121 Our data show that DRN 5-HT1A receptor availability is linked specifically to t

122 However, it is unknown whether 5-HT1A receptor availability is linked specifically to t

123 we tested drugs that stimulate serotonin 1A (5-HT1A) receptors, based on our previous findings that t

124 ent study, it was found that blockade of the 5-HT(1A) receptor before and after pilocarpine treatment

125 found between 5-HT neuron count or density, 5-HT(1A) receptor binding density, or 5-HTT receptor bin

126 HT neurons, there was a decrease with age in 5-HT(1A) receptor binding in the SIDS cases but no chang

127 We estimated 5-HT(1A) receptor binding preoperatively with (18)F-tran

128 as well as a significantly lower density of 5-HT(1A) receptor binding sites (P<or=.01 for all 9 nucl

129 5-HT(1A) receptor binding was 29% to 55% lower in 3 medu

130 oleacetic acid (5-HIAA); levels of TPH2; and 5-HT(1A) receptor binding.

131 A significant increase in 5-HT1A receptor binding density was observed across infa

132 We observed increased 5-HT1A receptor binding in women who had recovered from

133 exception of the hypoglossal nucleus, where 5-HT1A receptor binding increases while SERT binding rem

134 5-HT1A receptor binding is also associated with treatmen

135 Regional estimates of 5-HT1A receptor binding potential (nondisplaceable) were

136 Specific 5-HT1A receptor binding was assessed using the binding p

137 However, 5-HT1A receptor binding was associated with a measure of

138 an age, 25.1 +/- 5.8 years).Intervention The 5-HT1A receptor binding was measured using positron emis

139 hey exhibit reduced 5-HT neuron activity and 5-HT1A receptor binding with varying changes in postsyna

140 s receptor decreases it, we examined whether 5-HT(1A) receptor blockade would prevent the seizure-ind

141 d by either 5-HT2A/C receptor stimulation or 5-HT1A receptor blockade of naive control pups.

142 The 5-HT(1A) receptor BP was inversely associated with heart

143 so blocked functional desensitization of DRN 5-HT(1A) receptors by uncontrollable stress.

144 nsitivity, suggesting that Rh-CT(5-HT1A) and 5-HT(1A) receptors compete to interact with the same tra

145 A receptor protomer in the hippocampal FGFR1-5-HT1A receptor complex enhancing the FGFR1 signaling.

146 r receptor 1 (FGFR1)-5-hydroxytryptamine 1A (5-HT1A) receptor complexes have been demonstrated and th

147 promoter, so that they are only expressed in 5-HT1A receptor-containing cells.

148 These data suggest that the 5-HT(1A) receptor contains high and moderate affinity Ca

149 The human 5-HT(1A) receptor contains two putative CaM binding moti

150 esults demonstrate that drugs that stimulate 5-HT1A receptors counteract respiratory abnormalities in

151 The serotonin 5-HT(1A) receptor couples to heterotrimeric G proteins a

152 unexpected, large increase in the inhibitory 5-HT(1A) receptor currents.

153 A strong correlation of 5-HT(1A) receptor decreases in hippocampus with worsenin

154 ssion tomography (PET) for quantification of 5-HT(1A) receptor densities in the living brains of Alzh

155 compromises the accuracy of measurements of 5-HT1A receptor densities in adjacent areas of brain bec

156 ts applicability to measuring brain regional 5-HT1A receptor densities.

157 esearch with PET for measuring serotonin 1A (5-HT1A) receptor densities in brain regions of human sub

158 ases in social behaviors are 5-HT2A, but not 5-HT1A, receptor dependent.

159 ffects of uncontrollable stress also blocked 5-HT(1A) receptor desensitization.

160 We determined that stimulation of the 5-HT1A receptor did not contribute to this improvement i

161 TM4/TM5 can form an interaction interface in 5-HT(1A) receptor dimers and indicates that specific ami

162 inding in rats was consistent with the known 5-HT(1A) receptors distribution (hippocampus and cortica

163 ) F-Mefway therefore may be used to quantify 5-HT1A receptor distribution in brain regions for the st

164 G protein-coupled receptor that targets into 5-HT(1A) receptor domains and substitutes for endogenous

165 titive control of Gi/o pathway activation in 5-HT1A receptor domains in the dorsal raphe nucleus (DRN

166 ic alpha1 and alpha2 receptors; serotonergic 5-HT1A receptors; dopaminergic D1/5 receptors by using q

167 5-HT(1A) receptors exist in high- and low-affinity state

168 The inhibitory serotonin-1A (5-HT(1A)) receptor exists in two separate populations wi

169 ion of the serotonin 5-hydroxytryptamine-1A (5-HT(1A)) receptor expressed in CHO-K1 cells.

170 be associated with sex-specific variation in 5-HT(1A) receptor expression.

171 l polymorphism in the promoter region of the 5-HT(1A) receptor gene is associated with depression and

172 orphism in the promoter of the serotonin-1A (5-HT(1A)) receptor gene in increased susceptibility to d

173 Altered regulation of the serotonin-1A (5-HT1A) receptor gene is implicated in major depression

174 activities at both the 5-HT transporter and 5-HT1A receptor, good selectivity over the alpha1-adrene

175 of the serotonin 1A (5-hydroxytryptamine 1A [5-HT(1A)]) receptor has been widely used in clinical stu

176 results reveal the broad dependence that the 5-HT1A receptor has on plasma membrane properties, demon

177 tonergic system, including the serotonin 1A (5-HT(1A)) receptor, has been implicated in the pathophys

178 5-HT1A receptors in line with evidence that 5-HT1A receptors have a role in mediating emotional proc

179 Serotonin 5-HT1A receptors have been implicated in disorders of th

180 Current PET radioligands targeting 5-HT1A receptors have limitations hindering widespread P

181 -HT1A autoreceptors by being part of a FGFR1-5-HT1A receptor heterocomplex in the midbrain raphe 5-HT

182 e cells, evidence for the existence of FGFR1-5-HT1A receptor heterocomplexes in the dorsal and median

183 that CaM binding and phosphorylation of the 5-HT(1A) receptor i3 loop peptides by protein kinase C a

184 (18) F-Mefway appears to be an effective 5-HT1A receptor imaging agent in all models, including h

185 uptake and, in turn, its spillover on brain 5-HT1A receptor imaging were assessed by PET with venous

186 gh the authors observed a greater density of 5-HT1A receptor immunoreactivity in H-Agg hamsters withi

187 2A), serotonin 2C (5-HT2C) and serotonin 1A (5-HT1A) receptors, implicated in the development of anxi

188 modulin (CaM) co-immunoprecipitates with the 5-HT(1A) receptor in Chinese hamster ovary fibroblasts.

189 tered serotonin transmission by means of the 5-HT(1A) receptor in dysfunction of prefrontal cortex py

190 onfirming the requirement for activating the 5-HT(1A) receptor in initiating this survival pathway.

191 also observed an increased expression of the 5-HT(1A) receptor in ipsapirone-treated control neurons.

192 transfer to show that CaM interacts with the 5-HT(1A) receptor in living cells, representing the firs

193 lso highlight the importance of the cortical 5-HT(1A) receptor in mediating cognition.

194 s of each receptor, Smo is equivalent to the 5-HT(1A) receptor in the assay as it relates to capacity

195 ity, and resulted in better visualization of 5-HT(1A) receptor in the brain.

196 tomography and [(11)C]WAY-100635 to quantify 5-HT(1A) receptors in a group of 31 healthy and unmedica

197 eased [(11)C]CUMI-101 BP(ND) at postsynaptic 5-HT(1A) receptors in several cortical regions, but ther

198 for probing the high-affinity states of the 5-HT(1A) receptors in vitro and in vivo.

199 Translation of imaging the 5-HT1A receptor in animal models to humans will facilita

200 adiotracer for PET experiments examining the 5-HT1A receptor in neuropsychiatric disorders and drug i

201 rements show simultaneous trafficking of the 5-HT1A receptor in two distinct endosomal recycling path

202 We therefore knocked down 5-HT1A receptors in either the dorsal raphe (presynaptic

203 ns of decreased immunoreactive perikarya and 5-HT1A receptors in fluoxetine-treated hamsters.

204 Knockdown of 5-HT1A receptors in hippocampus, but not dorsal raphe, s

205 rsive stimuli and that this is linked to DRN 5-HT1A receptors in line with evidence that 5-HT1A recep

206 of DA D2 receptors in mPFC or activation of 5-HT1A receptors in OFC increases impulsive choice in th

207 ial of 18F-FCWAY to act as a radioligand for 5-HT1A receptors in rat brain and also revealed extensiv

208 FCWAY, results in effective imaging of brain 5-HT1A receptors in rat.

209 e as an effective platform for investigating 5-HT1A receptors in rodent models of neuropsychiatric co

210 e influence of pharmacological activation of 5-HT1A receptors in specific brain regions, this neuroim

211 Finally, we demonstrate that activation of 5-HT1A receptors in the dBNST is necessary for the anxio

212 r the results suggest that the activation of 5-HT1A receptors in the DRN results from the local relea

213 hat serotonin signaling through postsynaptic 5-HT1A receptors in the hippocampus is critical for the

214 nd Ad-1AP-antisense) were used to manipulate 5-HT1A receptors in the hypothalamus.

215 The density and the function of 5-HT1A receptors in the medial hypothalamus were signifi

216 hypothalamus of SERT knock-out mice restored 5-HT1A receptors in the medial hypothalamus; this effect

217 support earlier findings that activation of 5-HT1A receptors in the mediobasal hypothalamus inhibits

218 itory effects of substance P, implicating DR 5-HT1A receptors in this response.

219 f research have implicated the serotonin 1A (5-HT1A) receptor in major depressive disorder (MDD).

220 ed decreased density of 5-hydroxytryptamine (5-HT1A) receptors in the hypothalamus, amygdala, and dor

221 or the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor in recombinant cells expressing human

222 etine persistently upregulated SERT, but not 5-HT1A receptors, in both the neocortex and the hippocam

223 Our goal was to determine whether 5-HT(1A) receptors inhibit opioid release in the spinal

224 These results show that 5-HT(1A) receptors inhibit opioid release in the spinal

225 Here, activated 5-HT1A receptors inhibit firing and, thereby, muscle con

226 Here we show that serotonin, by activating 5-HT(1A) receptors, inhibited NMDA receptor-mediated ion

227 e feedback onto receptor cells by activating 5-HT(1A) receptors, inhibiting taste-evoked Ca(2+) mobil

228 previous study has shown that activation of 5-HT(1A) receptors inhibits N-methyl-D-aspartate (NMDA)

229 The 5-HT(1A) receptor is a metabotropic G protein-coupled re

230 the serotonergic (5-HT) system, of which the 5-HT1A receptor is an essential component.

231 further demonstrate that tonic activation of 5-HT1A receptors is not responsible for the absence of s

232 Motor maps derived in 5-HT1A receptor knock-out mice also showed higher moveme

233 mBMMC from the 5-HT(1A) receptor knockout mouse (5-HT(1A)R(-/-)) did no

234 In contrast, 5-HT(1A) receptor levels and G-protein coupling is norma

235 d chronic stimulant effects of cocaine using 5-HT1A receptor ligands in autoreceptor preferring doses

236 5-HT1A receptor ligands were ineffective.

237 whereas fewer (approximately 30%) expressed 5-HT(1A) receptor-like immunoreactivity.

238 Therefore, 5-HT(1A) receptors likely decrease the analgesia produce

239 ily and displayed a preferential labeling of 5-HT(1A) receptors located in cingulate cortex.

240 5-HT(1A) receptor maximal binding in the temporal cortex

241 The serotonin 5-HT(1A) receptor may modulate some of the negative, cog

242 s favorable in vivo properties for serotonin 5-HT1A receptor measurements in humans.

243 Moreover, these decreases in 5-HT(1A) receptor measures correlate with decreased gluc

244 sis that the 5-HT(7) but not the 5-HT(5A) or 5-HT(1A) receptors mediate serotonergic phase shifts.

245 m, we provide the first reported profile for 5-HT(1A) receptor-mediated ERK activation using a panel

246 e, but not controllable, tail shock impaired 5-HT(1A) receptor-mediated inhibition of DRN neuronal fi

247 potential significance of these findings to 5-HT(1A) receptor-mediated inhibition of female rat lord

248 This process is underpinned by 5-HT1A receptor-mediated activation of G-protein-coupled

249 nhibitors during development, have amplified 5-HT1A receptor-mediated currents in adulthood.

250 ted depolarization and the appearance of the 5-HT1A receptor-mediated hyperpolarization appears to re

251 hesis in mouse DRN brain slices by recording 5-HT1A receptor-mediated inhibitory postsynaptic current

252 n slices evoked serotonin release produced a 5-HT1A receptor-mediated inhibitory postsynaptic current

253 for the role of progesterone in altering the 5-HT(1A) receptor modulation of lordosis behavior.

254 Here we used computational modeling of the 5-HT(1A) receptor monomer and dimer to predict residues

255 We also found divergent 5-HT1A receptor mRNA expression within some of these sam

256 ty, we investigated the impact of activating 5-HT1A receptors on post-C5 SCI respiratory dysfunction.

257 1A) receptor antagonist (pK(i) = 8.70) and a 5-HT(1A) receptor partial agonist (pK(i) = 9.25, pD(2) =

258 As serotonin 1A (5-HT1A) receptors participate in the inhibition of aggre

259 study provides class III evidence that both 5-HT(1A) receptor PET and CMRglc PET can contribute to t

260 a possible role for CaM in the regulation of 5-HT(1A) receptor phosphorylation and desensitization.

261 Brain serotonin 1A (5-HT1A) receptors play an important role in mood disorde

262 s demonstrate that serotonin, acting through 5-HT1A receptors, plays an excitatory role in forelimb m

263 ntributions of various pre- and postsynaptic 5-HT1A receptor populations to the behavioral effects of

264 lateral and medial parts of the CeA whereas 5-HT(1A) receptor positive neurones were located mainly

265 Availability of DRN 5-HT1A receptors positively correlated with amygdala con

266 y, in part, be mediated by activation of the 5-HT1A receptor protomer in the hippocampal FGFR1-5-HT1A

267 est to develop an (18)F-labeled full agonist 5-HT(1A) receptor radiotracer.

268 results demonstrate that medial hypothalamic 5-HT1A receptors regulate stress responses and locomotor

269 ey were blocked by antagonists of 5-HT2A and 5-HT1A receptors, respectively.

270 Targeted suppression of 5-HT(1A) receptor-responsive PPTn neurons also increased

271 These data indicate that 5-HT(1A) receptor-responsive PPTn neurons normally funct

272 Serotonin type 1A (5-HT(1A)) receptor-responsive neurons in the pedunculopo

273 ution of Rh-CT(5-HT1A) resembles that of the 5-HT(1A) receptor; Rh-CT(5-HT1A) localizes to somatodend

274 mediated, at least partially, by changes in 5-HT1A receptor sensitivity.

275 additional receptor-interacting proteins in 5-HT(1A) receptor signaling.

276 t 5-HTTLPR effect on receptor binding at the 5-HT(1A) receptor site has been reported in humans, sugg

277 s-carriers) to examine the relation between 5-HT(1A) receptor-specific binding and 5-HTTLPR genotype

278 Pretreatment with the 5-HT1A receptor-specific antagonist N-[2-[4-(2-methoxyph

279 5-HT(1A) receptor stimulation and 5-HT(6) and 5-HT(7) re

280 ists, further evidence for the importance of 5-HT(1A) receptor stimulation in the NOR deficit produce

281 e 5-HT(2A) receptor stimulation, relative to 5-HT(1A) receptor stimulation, both of which can increas

282 ortex, and that the effect is dependent upon 5-HT(1A) receptor stimulation.

283 t have an agonist/antagonist activity at the 5-HT(1A) receptor subtype are known to greatly potentiat

284 l gamma oscillations in both species via the 5-HT1A receptor subtype.

285 pathway--as during motor exercise--activated 5-HT1A receptors that decreased motoneuronal excitabilit

286 Here, we define a mechanism downstream of 5-HT1A receptors that mediates antidepressant-like behav

287 pression-related research has focused on the 5-HT1A receptor, the 5-HT1B receptor has a lesser known

288 on expression and signaling activity of the 5-HT(1A) receptor to a ligand with an intrinsic agonist

289 To evaluate the contribution of hypothalamic 5-HT1A receptors to these phenotypes of SERT knock-out m

290 he dBNST modulates anxiety-like behavior via 5-HT1A receptors under naturalistic conditions.

291 This effect of 5-HT(1A) receptors was blocked by agents that interfere

292 effect of WAY-100,635, an antagonist to the 5-HT(1A) receptors, was tested.

293 In addition, while the effects of the 5-HT1A receptor were limited, the broad effects of 5-HT3

294 m being protective led to desensitization of 5-HT(1A) receptors, whereas treatments that block the be

295 omography (PET) imaging studies of serotonin 5-HT1A receptors which are implicated in various brain f

296 with an antibody against the serotonin(1A) (5-HT(1A)) receptor, which also mediates inhibitory regul

297 ferent aspects of the depolarization, and of 5-HT1A receptors, which signal the late developing hyper

298 inds selectively to the 5-hydroxytryptamine (5-HT1A) receptor, which is expressed on pyramidal neuron

299 nergic modulation of 5-hydroxytryptamine 1A (5-HT1A) receptors, which hyperpolarizes the activation r

300 e electrophysiological effects of prefrontal 5-HT1A receptors with implications for neuropsychiatric

301 Interactions between NK1 and 5-HT1A receptors within DR neural networks may contribut